Leerink Partners Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Jeffrey La Rosa has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with an Outperform rating and set a price target of $12 for the company's stock.
January 23, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners initiated coverage on Pyxis Oncology with an Outperform rating and a price target of $12, which could positively influence the stock's performance.
Analyst coverage, especially with an Outperform rating, tends to generate positive sentiment among investors and can lead to an increase in stock price. The price target of $12 suggests a significant upside from the current trading level, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100